Announcements Trials
Browse Landscape

Status

Completed 2477Terminated 673Recruiting 588Unknown 486Active not recruiting 342Withdrawn 185Not yet recruiting 121Suspended 23No longer available 20Enrolling by invitation 19Available 5Approved for marketing 3

Sponsor Class

INDUSTRY 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

Thoracic 17Gastrointestinal 13Other hematologic neoplasm 12Genitourinary 12Lymphoid 10Breast 10CNS 7Plasma cell 6Head & Neck 5Endocrine 5Sarcoma 4Tumor-Agnostic 3Dermatologic 3NET 2Myeloid 2Gynecologic 2Other solid neoplasm 1

Conditions

Carcinoma, Basal Cell 2Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

cemiplimab 1avelumab 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Approved for marketing × Dermatologic × Clear all
NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Approved for marketing
DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT03089658 2019-10-09

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Merck KGaA, Darmstadt, Germany

Approved for marketing
Dermatologic

Carcinoma, Merkel Cell

NCT01160250 2015-08-06

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Genentech, Inc.

Approved for marketing
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡